Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy
Background. Extracellular adenosine 5′-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain–Barré syndrome (GBS) and chronic inflammat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2024/7229216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850174590888706048 |
|---|---|
| author | Takamasa Nukui Hideki Niimi Tomohiro Hayashi Nobuhiro Dougu Mamoru Yamamoto Ryoko Shibuya Noriyuki Matsuda Ryo Tanaka Hiroaki Hirosawa Risako Furuta Taichi Mitsui Hiroki Maesaka Syuhei Takasawa Isao Kitajima Yuji Nakatsuji |
| author_facet | Takamasa Nukui Hideki Niimi Tomohiro Hayashi Nobuhiro Dougu Mamoru Yamamoto Ryoko Shibuya Noriyuki Matsuda Ryo Tanaka Hiroaki Hirosawa Risako Furuta Taichi Mitsui Hiroki Maesaka Syuhei Takasawa Isao Kitajima Yuji Nakatsuji |
| author_sort | Takamasa Nukui |
| collection | DOAJ |
| description | Background. Extracellular adenosine 5′-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity. Methods. CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs). In patients with CIDP, CSF ATP levels were compared before and after treatment. The correlations between CSF ATP levels and other factors, including clinical data and CSF protein levels, were also evaluated. Results. Median CSF ATP levels were significantly higher in patients with GBS and CIDP than in those with ONDs. When patients with CIDP were classified into two groups depending on their responsiveness to immunotherapy, median CSF ATP levels were significantly higher in good responders than in ONDs. CSF ATP levels tended to decrease after treatment in patients with CIDP. In patients with CIDP, there is a negative correlation between CSF ATP and CSF protein levels. Conclusions. CSF ATP levels were increased in patients with GBS and CIDP. In particular, CSF ATP levels tended to decrease following treatment in patients with CIDP. CSF ATP levels may be useful biomarkers for the diagnosis or monitoring of therapeutic effects in patients with GBS and CIDP. |
| format | Article |
| id | doaj-art-cab707569a3546ecaeffcfa6abae502c |
| institution | OA Journals |
| issn | 2090-1860 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-cab707569a3546ecaeffcfa6abae502c2025-08-20T02:19:37ZengWileyNeurology Research International2090-18602024-01-01202410.1155/2024/7229216Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating PolyneuropathyTakamasa Nukui0Hideki Niimi1Tomohiro Hayashi2Nobuhiro Dougu3Mamoru Yamamoto4Ryoko Shibuya5Noriyuki Matsuda6Ryo Tanaka7Hiroaki Hirosawa8Risako Furuta9Taichi Mitsui10Hiroki Maesaka11Syuhei Takasawa12Isao Kitajima13Yuji Nakatsuji14Department of NeurologyDepartment of Clinical Laboratory and Molecular PathologyDepartment of NeurologyTakaoka City HospitalDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of Clinical Laboratory and Molecular PathologyDepartment of NeurologyBackground. Extracellular adenosine 5′-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity. Methods. CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs). In patients with CIDP, CSF ATP levels were compared before and after treatment. The correlations between CSF ATP levels and other factors, including clinical data and CSF protein levels, were also evaluated. Results. Median CSF ATP levels were significantly higher in patients with GBS and CIDP than in those with ONDs. When patients with CIDP were classified into two groups depending on their responsiveness to immunotherapy, median CSF ATP levels were significantly higher in good responders than in ONDs. CSF ATP levels tended to decrease after treatment in patients with CIDP. In patients with CIDP, there is a negative correlation between CSF ATP and CSF protein levels. Conclusions. CSF ATP levels were increased in patients with GBS and CIDP. In particular, CSF ATP levels tended to decrease following treatment in patients with CIDP. CSF ATP levels may be useful biomarkers for the diagnosis or monitoring of therapeutic effects in patients with GBS and CIDP.http://dx.doi.org/10.1155/2024/7229216 |
| spellingShingle | Takamasa Nukui Hideki Niimi Tomohiro Hayashi Nobuhiro Dougu Mamoru Yamamoto Ryoko Shibuya Noriyuki Matsuda Ryo Tanaka Hiroaki Hirosawa Risako Furuta Taichi Mitsui Hiroki Maesaka Syuhei Takasawa Isao Kitajima Yuji Nakatsuji Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Neurology Research International |
| title | Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy |
| title_full | Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy |
| title_fullStr | Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy |
| title_full_unstemmed | Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy |
| title_short | Increased Cerebrospinal Fluid Adenosine 5′-Triphosphate Levels in Patients with Guillain–Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy |
| title_sort | increased cerebrospinal fluid adenosine 5 triphosphate levels in patients with guillain barre syndrome and chronic inflammatory demyelinating polyneuropathy |
| url | http://dx.doi.org/10.1155/2024/7229216 |
| work_keys_str_mv | AT takamasanukui increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT hidekiniimi increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT tomohirohayashi increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT nobuhirodougu increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT mamoruyamamoto increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT ryokoshibuya increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT noriyukimatsuda increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT ryotanaka increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT hiroakihirosawa increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT risakofuruta increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT taichimitsui increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT hirokimaesaka increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT syuheitakasawa increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT isaokitajima increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy AT yujinakatsuji increasedcerebrospinalfluidadenosine5triphosphatelevelsinpatientswithguillainbarresyndromeandchronicinflammatorydemyelinatingpolyneuropathy |